"We are very pleased with the decision. It confirms our belief that Boston Scientific is at the forefront of innovation and has fundamental intellectual property in the treatment of coronary artery disease," said Paul LaViolette, Boston Scientific's Chief Operating Officer. "We are hopeful that it will provide an opportunity for a fair and reasonable settlement of the numerous disputes between our two companies."
Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation and other factors described in the Company's filings with the Securities and Exchange Commission.